Evaluating Intracranial Response with DXd ADCs & Other Biologics: Lessons Learned & Opportunities Ahead

  • Traditionally, large molecules including ADCs are thought to have no intracranial efficacy due to inability to cross the blood brain barrier
  • Presenting evidence of intracranial efficacy of multiple DXd ADCs and mAbs, challenging this dogma
  • Explaining this information can be utilised to address the unmet needs for patients with brain metastases